Company Description

Revolution Medicines, Inc., a clinical-stage precision oncology company, focuses on developing therapies to inhibit frontier targets in RAS-addicted cancers.

The company is developing RMC-4630, an inhibitor of SHP2, which is in Phase 1/2 clinical trial for the treatment of solid tumors, such as gynecologic and colorectal cancer tumors.

It also develops RMC-5845, a selective inhibitor of SOS1, a protein that converts RAS (OFF) to RAS (ON) in cells; and RMC-5552, a hyperactivated selective inhibitor of mTORC1 signaling in tumors.

In addition, the company is developing RMC-6291, a mutant-selective inhibitor of KRASG12C(ON) and NRASG12C(ON); and RMC-6236, a RAS-selective inhibitor of multiple RAS(ON) variants.

Further, it develops RAS(ON) Inhibitors targeting KRASG13C(ON) and KRASG12D(ON).

The company has a collaboration agreement with Sanofi for the research and development of SHP2 inhibitors, including RMC-4630.

Revolution Medicines, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.